Relevant bibliographies by topics / Immune-related adverse effect

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Immune-related adverse effect'

Author: Grafiati
Published: 21 September 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immune-related adverse effect.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immune-related adverse effect"

1

Bangalore Kumar, Anagha, Alan Bryce, Prakash Vishnu, Svetomir Markovic, and Marian McEvoy. "Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma." SKIN The Journal of Cutaneous Medicine 5, no. 2 (2021): 108–17. http://dx.doi.org/10.25251/skin.5.2.5.

Full text
Abstract:
Background: Dermatologic toxicity is the most common immune-related adverse effect of cancer immunotherapy.
 Methods: We retrospectively reviewed the health records of adult (≥18 years) melanoma patients who received ipilimumab, nivolumab, or pembrolizumab from January 1, 2011, through September 15, 2017, at Mayo Clinic. The χ2 test was used to assess the association between development of a cutaneous immune-related adverse effect and antitumoral response to the immune checkpoint inhibitors. Odds ratios were calculated with logistic regression models and were adjusted for sex and immunoth
APA, Harvard, Vancouver, ISO, and other styles
2

Williams, Kiersten J., Dennis W. Grauer, David W. Henry, and Michelle L. Rockey. "Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors." Journal of Oncology Pharmacy Practice 25, no. 3 (2017): 544–50. http://dx.doi.org/10.1177/1078155217744872.

Full text
Abstract:
Introduction Due to enhanced T-cell activity, immune checkpoint inhibitors cause immune-related adverse effects. Corticosteroids are the mainstay of immune-related adverse effect management but the optimal strategy has not been determined, putting patients at risk for steroid-related adverse effects and potentially decreased efficacy of immunotherapy. This study aims to characterize the use of corticosteroids for the management of immune-related adverse effect. Methods and materials A retrospective, single-center evaluation of patients receiving checkpoint inhibitors was conducted. The primary
APA, Harvard, Vancouver, ISO, and other styles
3

Muir, Christopher A., Roderick J. Clifton-Bligh, Georgina V. Long, et al. "Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment." Journal of Clinical Endocrinology & Metabolism 106, no. 9 (2021): e3704-e3713. http://dx.doi.org/10.1210/clinem/dgab263.

Full text
Abstract:
Abstract Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical presentation can be variable. Objective This study sought to define thyroid irAEs following immune checkpoint inhibitor (ICI) treatment and describe their clinical and biochemical associations. Methods We performed a retrospective cohort study of thyroid dysfunction in patients with melanoma undergoing cytotoxic T-lymphocyte antigen-4 (CTLA-4) and/or programmed cell death protein-1 (PD-1) based ICI treatment from
APA, Harvard, Vancouver, ISO, and other styles
4

Lima, Gian, Adriana Kahn, Shashank Sama, and Jacqueline Savage. "Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab." Case Reports in Oncological Medicine 2019 (November 4, 2019): 1–2. http://dx.doi.org/10.1155/2019/7183747.

Full text
Abstract:
Introduction. The management of patients with advanced malignancies is challenging, although recent advances with immunotherapy have shown better outcomes. Pembrolizumab has been associated with a variety of immune-related side effects, but the occurrence of aseptic meningitis is rare. Case. A 55-year-old male with a history of metastatic lung adenocarcinoma previously treated with pembrolizumab presented with persistent severe headaches and photophobia. Subsequent workup with cerebrospinal fluid analysis showed elevated opening pressure, increased nucleated cells with 30% lymphocytes, elevate
APA, Harvard, Vancouver, ISO, and other styles
5

Bansal, Aditi, Ankur Singla, Davinder Paul, and Sukhjot Kaur. "Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect." Indian Dermatology Online Journal 14, no. 3 (2023): 391. http://dx.doi.org/10.4103/idoj.idoj_377_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kim, Won Myung, Mun Su Park, Dong Hyun Seo, Jung Yun Lee, and Jung Yoon Pyo. "Immune-related Adverse Effect after BNT162b2 Vaccination with Parallel Immune Checkpoint Inhibitor Therapy: A Case Report." Korean Journal of Medicine 98, no. 2 (2023): 93–97. http://dx.doi.org/10.3904/kjm.2023.98.2.93.

Full text
Abstract:
COVID-19 vaccination is essential in cancer patients. However, there is limited evidence of the prognosis of these patients, especially for those taking immune checkpoint inhibitors (ICIs). We present a patient on pembrolizumab for advanced endometrioid adenocarcinoma experiencing continuous diarrhea and subsequent episodes of fever with pain in multiple joints following a second dose of the BNT162b2 mRNA COVID-19 vaccine. An ICI-induced immune-related adverse effect (irAE) was the main diagnosis; cytokine release syndrome and rheumatoid arthritis were also considered. Notably, the novel irAE
APA, Harvard, Vancouver, ISO, and other styles
7

Brinzevich, Daria, Virginia Falvello, Michael D. Green, and Alex Bryant. "Impact of commonly prescribed medications on immune-related adverse events." Journal of Clinical Oncology 42, no. 16_suppl (2024): e14704-e14704. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14704.

Full text
Abstract:
e14704 Background: Commonly used medications may have immune modulating properties that affect the risk of immune-related adverse events (irAEs) after immune checkpoint inhibitor (ICI) therapy. Methods: We identified 27,998 patients who received ICI from 2010 to 2023 in the national Veterans Affairs system, matched to 66,488 historical control patients treated with non-ICI systemic therapies. We extracted medication usage in the year before therapy start. We used propensity-weighted Cox regression analysis to assess the effect of each medication on severe irAE (treatment with prolonged course
APA, Harvard, Vancouver, ISO, and other styles
8

Ou, Qiyun, Yunfang Yu, Haitao Zhong, et al. "Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14087-e14087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14087.

Full text
Abstract:
e14087 Background: Immune-related adverse events (irAEs) have been shown to be associated with the efficacy of immune checkpoint inhibitors in patients with advanced cancer, but the reported effect sizes have varied greatly in previous trials. We did a meta-analysis to assess immune checkpoint inhibitors efficacy and further explored the correlation of irAEs with efficacy in cancer. Methods: We systematically searched database inception to January, 2019 for randomized trials of immune checkpoint inhibitor in patients with advanced cancer that had available data for overall survival (OS) and pr
APA, Harvard, Vancouver, ISO, and other styles
9

Hamatake, Kiyonori, and Kazuaki Kojima. "Initiatives for immune-related adverse events by the outpatient pharmacist clinic." Trends in Immunotherapy 6, no. 1 (2022): 3. http://dx.doi.org/10.24294/ti.v6.i1.1385.

Full text
Abstract:
Early detection is the key in managing side effects because immune-related adverse events (irAEs) are becoming more serious, and their onset time differs. In our hospital, we conducted an outpatient pharmacist clinic for early detection of irAEs by self-care practice for the cases of immune checkpoint inhibitor administration. As a result of a retrospective survey of 207 cases, the percentage of irAEs found by pharmacist’s suggestion of the outpatient pharmacist clinic increased over time, and a high detection ratio was obtained even for irAEs with a late onset time. The incidence of serious i
APA, Harvard, Vancouver, ISO, and other styles
10

Elsayed, Manar, and Carrie Ye. "Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?" Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e009309. http://dx.doi.org/10.1136/jitc-2024-009309.

Full text
Abstract:
The widespread use of immune checkpoint inhibitors (ICIs) in clinical practice has broadened our understanding of their immune-related adverse events (irAEs). IrAEs, including musculoskeletal adverse events, remain a significant concern. While ICI-associated arthritis is a well-documented musculoskeletal side effect of ICI therapy, the direct effects of ICIs on bone in patients with cancer are poorly understood. There is emerging evidence to support the hypothesis that ICIs adversely impact bone turnover and can lead to osteoporosis and fragility fractures, which are not currently recognized a
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immune-related adverse effect"

1

L'Orphelin, Jean-Matthieu. "Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV". Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC406.

Full text
Abstract:
Contexte. Les inhibiteurs de point de contrôle immunitaire sont le traitement de première ligne incontesté des mélanomes de stade IV et sont pourvoyeurs d’effets indésirables, souvent immuno-médiés. Il existe une prise en compte croissante des événements immuno-médiés dans la décision thérapeutique et une volonté d’individualisation des prises en charges des patients atteints de mélanome métastatique. Une caractérisation plus fine ce ces événements permettrait une meilleure prédiction de leur survenue et de leurs impacts. Nos connaissances des événements immuno-médiés proviennent majoritaireme
APA, Harvard, Vancouver, ISO, and other styles
2

Soussan, Sarah. "B lymphocytes and autoantibodies in immune-related adverse events following immune checkpoint inhibitors in cancer patients." Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS022.pdf.

Full text
Abstract:
Les anticorps monoclonaux thérapeutiques ciblant les inhibiteurs de checkpoints immunitaires, tels que PD-1 et CTLA-4, ont pour objectif d'induire la réactivation de l'immunité anti-tumorale. Cependant, une limite à l'utilisation de ces immunothérapies anti-cancéreuses est l'émergence de toxicités auto-immunes ou irAEs (« immune-related adverse events »). La survenue d'effets secondaires spécifiquement associés à ce type de traitement est observée chez 30 à 90% des patients. De plus, les toxicités peuvent nécessiter une réduction ou un arrêt de l'immunothérapie. Des premières études ont démont
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Immune-related adverse effect"

1

J, Herzyk Danuta, and Bussiere Jeanine L, eds. Immunotoxicology strategies for pharmaceutical safety assessment. John Wiley & Sons, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1929-, Newcombe David S., Rose Noel R, and Bloom John C, eds. Clinical immunotoxicology. Raven Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bussiere, Jeanine L., and Danuta J. Herzyk. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons, Incorporated, John, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bussiere, Jeanine L., and Danuta J. Herzyk. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons, Incorporated, John, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons Canada, Limited, John, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dietert, Rodney R. Immunotoxicity Testing: Methods and Protocols. Humana Press, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Coyle, Patricia K. Immune-mediated Disorders of the Central Nervous System. Edited by Emma Ciafaloni, Cheryl Bushnell, and Loralei L. Thornburg. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190667351.003.0010.

Full text
Abstract:
This chapter reviews pregnancy in multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute transverse myelitis (ATM) syndrome. MS is a major acquired disease of young adults, with a rising female predominance. MS has no direct negative consequences on fertility or pregnancy. Pregnancy has a profound effect on MS, with decrease in disease activity during the last trimester counteracted by a three-month postpartum increase in disease activity. With the development of disease-modifying therapies, important questions arise about washout periods, the feasibility and risks
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Immune-related adverse effect"

1

Sahip Yesiralioglu, Birsen, Sehmus Ertop, Muzeyyen Aslaner Ak, and Hatice Ayag. "Types of Immunotherapy, Mechanism of Action and Side Effects." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.2.

Full text
Abstract:
Immunotherapy has emerged as a ground breaking approach in the treatment of various cancers and autoimmune diseases, utilizing the body’s immune system to combat disease. This article reviews the mechanisms of action of different types of immunotherapy, including checkpoint inhibitors, monoclonal antibodies, and adaptive cell transfer. Checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 blockers enhance immune responses by releasing brakes on T cells, thereby promoting anti-tumor immunity. Monoclonal antibodies target specific antigens on cancer cells or immune cells, facilitating targeted des
APA, Harvard, Vancouver, ISO, and other styles
2

Pawankar, Ruby, Cezmi A. Akdis, and Kari Nadeau. "Climate Change, Environment, and One Health." In Wellbeing, Values and Lifestyles. Springer Nature Singapore, 2025. https://doi.org/10.1007/978-981-97-4730-6_17.

Full text
Abstract:
Abstract Global epidemiological studies have revealed that climate change has led to a decrease in biodiversity and has been responsible for the pollution of air, water, and food, including the presence of microplastics. These factors have contributed to the rise of various non-communicable diseases (NCDs). As a result, the overall expenses related to healthcare, work productivity, mental health, and the economic situation of nations, particularly those with limited resources, have been adversely affected. The human exposome, epithelial barriers, microbiome and immune system are all affected l
APA, Harvard, Vancouver, ISO, and other styles
3

Agolti, Mariela, and Lucrecia Solari. "Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_2.

Full text
Abstract:
AbstractIntroduction: Immunotherapy is a wide-spreading therapeutic resource in oncology. The therapy is guided to improve the patient’s immune response to cancer cells, on the basis of the concept of immune surveillance by activating both cell-mediated and humoral immunity to fight cancer. Immunomodulatory monoclonal antibody therapy utilizes preformed monoclonal antibodies directed against molecular targets to regulate T-cell activation. There are three mechanisms involved in this kind of therapy: antibodies directed against the programmed death protein 1 (PD-1)/programmed death receptor lig
APA, Harvard, Vancouver, ISO, and other styles
4

Saccardi, Riccardo, and Fermin Sanchez-Guijo. "How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified?" In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_38.

Full text
Abstract:
AbstractThe FACT-JACIE accreditation system is based on a standard-driven process covering all the steps of HSC transplant activity, from donor selection to clinical care. Since the first approval of the First Edition of the Standards in 1998, over 360 HSCT programmes or facilities have been accredited at least once, most of them achieving subsequent re-accreditations (Snowden et al. 2017). The positive impact of the accreditation process in the EBMT Registry has been well established (Gratwohl et al. 2014). Starting with version 6.1, the standards include new items specifically developed for
APA, Harvard, Vancouver, ISO, and other styles
5

Bhattacharyya, Joya, and Arthur Kaser. "Immune disorders of the gastrointestinal tract." In Oxford Textbook of Medicine, edited by Jack Satsangi. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0292.

Full text
Abstract:
Immune homeostasis in the gut is the result of a delicate balance between peaceful coexistence with commensal microbiota, immunomodulatory effects of dietary antigens, and appropriate responses to pathogens. Immune disorders of the gut arise when defects in the integrity of these components lead to a dysregulated immune response to the commensal environment. Primary immunodeficiency syndromes can present with intestinal inflammation but are commonly characterized by an increased susceptibility to infections in childhood. Secondary immunodeficiency can occur in a protein-losing enteropathy wher
APA, Harvard, Vancouver, ISO, and other styles
6

"Model-based meta-analysis of adverse events in metastatic melanoma immunotherapy: The importance of quantifying heterogeneity." In Book of Abstracts - RAD 2025 Conference. RAD Centre, Niš, Serbia, 2025. https://doi.org/10.21175/rad.abstr.book.2025.7.2.

Full text
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have reshaped the management of advanced melanoma, offering a substantial survival advantage over conventional therapies. However, the therapeutic benefits of ICIs are accompanied by substantial immune-related adverse events (irAEs), which may severely impact patients’ quality of life and treatment adherence. These toxicities, arising from immune system dysregulation, vary in frequency and severity across treatment types, particularly between monotherapy and combination immunotherapy. This variability underscores the need for rigorous statis
APA, Harvard, Vancouver, ISO, and other styles
7

Davicino, Roberto C., and Claudia Anesini. "Immunomodulatory Plant Extracts and their Compounds. Evaluation of your Safety." In Advanced Pharmacy. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815049428123010010.

Full text
Abstract:
Medicinal herbs have been in use for the management of human health, for prevention. as well as for the cure of human diseases since ancient civilizations. In recent times, the use of herbal drugs has increased in both developed and developing countries, because of the large chemical, pharmacological, and clinical knowledge of plant drugs and their derivatives, the development of new analytical methods for quality control, the development of new forms of preparation and administration of plant drugs and their derivatives and finally the relatively wide therapeutic margins with less frequent ad
APA, Harvard, Vancouver, ISO, and other styles
8

Burton, Rosie, and Ana Houston. "HIV medicine." In Oxford Handbook of Tropical Medicine 5e. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198810858.003.0003.

Full text
Abstract:
Epidemiology, Virology and immunology, infection, Antiretroviral therapy, opportunistic infections, Antiretroviral drugs, doses and adverse effects, viral failure, Common clinical problems in HIV, HIV-related malignancy, Immune Reconstitution Inflammatory Syndrome (IRIS), HIV prevention strategies, Prevention of mother to child transmission (PMTCT), Post-exposure prophylaxis
APA, Harvard, Vancouver, ISO, and other styles
9

Rivera-Grana, Erick, and Stephanie M. Llop. "Immunotherapy-Associated Uveitis." In Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106442.

Full text
Abstract:
Novel immunotherapies used to treat some cancers, such as checkpoint inhibitors and target therapies of B-RAF protooncogene and mitogen-activated protein kinase (BRAF/MEK), have been strongly associated with adverse events related to immune dysregulation. These effects are known as immune-related adverse events (irAEs). Uveitis is among the known irAEs, and it occurs in approximately 1% of patients using these therapies. The uveitis observed in these patients ranges from anterior, intermediate, to panuveitis. If irAEs are severe, current recommendations are to stop immunotherapy treatment and
APA, Harvard, Vancouver, ISO, and other styles
10

Patel, Anush, Haisam Abid, and Amrat Kumar. "The Endocrinological Side Effects of Immunotherapies." In Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96491.

Full text
Abstract:
The use of immunotherapies is gaining importance in the treatment of advanced malignancies. There are many checkpoints in the immune system which prevents T-cells from attacking one’s own body cells. The cancer cells can camouflage from the T-cells and the immune system is unable to mount an effective anti-tumor response. The immunotherapies, mainly monoclonal antibodies anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), anti-programmed cell death protein-1 (PD-1) and anti-PD-1 ligand molecules (PD-L1 and L2) reactivate the immune system to act against cancerous cells but they can also cause T-ce
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immune-related adverse effect"

1

Yenepalli, A., L. Luna Diaz, and L. Eggert. "Asthma as an Immune-Related Adverse Effect of Pembrolizumab." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vitek, Grace, and Harjot Hansra. "Two Cases of Anti-PD1 Antibody Associated Neurological Immune-Related Adverse Effects (P5-4.001)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000203811.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Richter, M. D., C. S. Crowson, L. A. Kottschade, H. D. Finnes, S. N. Markovic, and U. Thanarajasingam. "SAT0588 Rheumatologic immune-related adverse effects of checkpoint inhibitor therapy: a single centrecohort of 29 patients." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kandolf Sekulović, Lidija. "TOXICITIES OF TARGETED THERAPY AND IMMUNE-RELATED ADVERSE DRUG REACTIONS OF IMMUNOTHERAPY IN THE TREATMENT OF METASTATIC MELANOMA." In Okrugli sto s međunarodnim učešćem "Melanom". Akademija nauka i umjetnosti Bosne i Hercegovine, 2018. http://dx.doi.org/10.5644/pi2019.180.04.

Full text
Abstract:
Targeted therapy and immunotherapy changed the treatment landscape for metastatic melanoma, which is chemotherapy resistant cancer. In pre-innovation era, the overall survival of patients with metastatic melanoma was 6 months, while today 5-year overall survival rate of 34% (and 50% in good prognostic groups) is evident. However, both treatments have their side effects, and cutaneous are the most frequent. Treating physicians in oncology centres, but also primary care specialists, need to be aware of their spectrum which differs for each class of drug: BRAF inhibitors, MEK inhibitors and immun
APA, Harvard, Vancouver, ISO, and other styles
5

Sklodowski, Kamil, Vito Dozio, Roberta Poli, et al. "Abstract 1615: Immune-related adverse effects (irAEs) associated proteomic profile in late-stage NSCLC patients after PD-1 blockade." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kostine, M., E. Mauric, L. Rouxel, et al. "OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

MONBRUN, Mathilde, Léo Grassion, Elodie Blanchard, Rémi Veillon, Maeva Zysman, and Chantal Raherison. "Influenza and Pneumococcal vaccination effects on the immune-related adverse events in patients under immunotherapy for an advanced stage non-small cell lung cancer." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa2303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Okpasuo, Onyekachi J., and Diana Gil. "470 Towards optimizing clinical performance of anti-cancer immunotherapies: Anti-CD3epsilon Mono-Fab enhances T cell anti-tumor responses without inducing immune related adverse effects." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0470.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Barreto, Everton Rodrigo, Rosana Maria Faria Vador, and Thalita Martins Ferraz Meneses. "Nurse performance in viral oncolytic therapy." In III SEVEN INTERNATIONAL MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/seveniiimulti2023-084.

Full text
Abstract:
Introduction: Viral oncolytic therapy (VOT) is an emerging approach in cancer treatment, which is based on the selective replication of a viral vector inside cancer cells, triggering the death of tumor cells by lysis and the spread of new viral particles to the remaining adjacent malignant cells. However, special care is needed from nurses to manage immune-mediated side effects and provide support and education to patients and their families during treatment. Objectives: To survey the nurse's performance in the face of VOT; propose a model of Systematization of Nursing Care (SNC) with the main
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immune-related adverse effect' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography